Tarsus execs discuss origins, treating Demodex blepharitis

Tarsus Pharmaceuticals's CEO Bobby Azamian, MD, PhD, and Chairman Michael Ackermann, PhD, speak on the development of their company and the latest updates on their lead candidate product to treat Demodex blepharitis.

Related Videos

Related Content

New data reveal molecular drivers of TED may remain activated in patients with low Clinical Activity Score

November 3rd 2022

Comparing micro-bypass implant + phaco vs phaco in POAG

December 23rd 2020

Verana Health + AAO IRIS Registry joint initiative yields 3.5 million ophthalmic images

October 31st 2022

Integrating AI to manage DR in a primary care setting

December 1st 2020

Centricity Vision’s new ZEPTO Plus handpiece gives surgeons a choice in capsulotomy size

October 26th 2022

Real World Ophthalmology networking offers early-practice career advice

October 19th 2022

New data reveal molecular drivers of TED may remain activated in patients with low Clinical Activity Score

November 3rd 2022

Comparing micro-bypass implant + phaco vs phaco in POAG

December 23rd 2020

Verana Health + AAO IRIS Registry joint initiative yields 3.5 million ophthalmic images

October 31st 2022

Integrating AI to manage DR in a primary care setting

December 1st 2020

Centricity Vision’s new ZEPTO Plus handpiece gives surgeons a choice in capsulotomy size

October 26th 2022

Real World Ophthalmology networking offers early-practice career advice

October 19th 2022

New data reveal molecular drivers of TED may remain activated in patients with low Clinical Activity Score

November 3rd 2022

Comparing micro-bypass implant + phaco vs phaco in POAG

December 23rd 2020

Verana Health + AAO IRIS Registry joint initiative yields 3.5 million ophthalmic images

October 31st 2022

Integrating AI to manage DR in a primary care setting

December 1st 2020

Centricity Vision’s new ZEPTO Plus handpiece gives surgeons a choice in capsulotomy size

October 26th 2022

Real World Ophthalmology networking offers early-practice career advice

October 19th 2022

Related Content

---

New data reveal molecular drivers of TED may remain activated in patients with low Clinical Activity Score

Article

---

Comparing micro-bypass implant + phaco vs phaco in POAG

Podcast

---

Verana Health + AAO IRIS Registry joint initiative yields 3.5 million ophthalmic images

Article

---

Integrating AI to manage DR in a primary care setting

Podcast

---

Centricity Vision’s new ZEPTO Plus handpiece gives surgeons a choice in capsulotomy size

Article

---

Real World Ophthalmology networking offers early-practice career advice

Article